In carcinoma cells neither COX-2 nor aromatase expression alone were able to select groups of patients with superior benefit from tamoxifen therapy, but for patients with aromatase positive tumors a high PR expression identified a group of patients for whom endocrine treatment resulted in significantly longer TTP (P = 0.023). The gene discussed is PGR; the disease is carcinoma.